Exelixis and GlaxoSmithKline will end their six-year collaboration based on its success, on October 27, 2008, as scheduled. Under the terms of the collaboration, GSK has the right to select two compounds for further development and commercialization. Exelixis will have the right to develop and commercialize compounds not selected by GSK. Exelixis’ exclusivity obligations will now be limited to the compounds selected by GSK. Exelixis will have the right to develop and commercialize any coll...